Product Details
Source
Anti-SARS-CoV-2 Nucleocapsid Antibody, Mouse IgG1 (AS47) (NUN-S47) was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified recombinant SARS-CoV-2 Nucleocapsid protein. The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. ELISA test validated that this antibody can bind multiple N protein variants (Cat. No. NUN-C52H8) with similar affinity as compared to the wild type N protein (Cat. No. NUN-C5227).
Clone
AS47
Species
Mouse
Isotype
Mouse IgG1 | Mouse Kappa
Conjugate
Unconjugated
Reactivity
Virus
Specificity
This product is a specific antibody against SARS-CoV-2 Nucleocapsid protein. No cross-reactivity is detected with nucleocapsid protein of other coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1.
Application
ApplicationRecommended UsageELISA0.1-10 ng/mLPurity
95% as determined by SDS-PAGE.
Purification
Protein A purified / Protein G purified
Formulation
Supplied as 0.2 μm filtered solution in PBS, pH7.4 .
Contact us for customized product form or formulation.
Shipping
This product is supplied and shipped with blue ice, please inquire the shipping cost.
Storage
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- For long term storage, the product is stable for up to 12 months at -70°C from date of receipt;
- For short term storage, the product is stable for up to 3 months at 2-8°C from date of receipt.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

Anti-SARS-CoV-2 Nucleocapsid Antibody, Mouse IgG1 (AS47) on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA

Immobilized SARS-CoV-2 Nucleocapsid protein, His Tag (Cat. No. NUN-C5227) at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Nucleocapsid Antibody, Mouse IgG1 (AS47) (Cat. No. NUN-S47) with a linear range of 0.15-2.5 ng/mL (QC tested).
Protocol
Customer Reviews Writing Reviews

Background
Recent Advances
- English Name:
Nucleocapsid proteins
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
1 Details
- Highest Development Stage:
Phase 1 Clinical
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
















